Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business

BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China

BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.

The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China, the two companies said in a statement.

BioNTech is also working with U.S. pharma giant Pfizer on the vaccine and the partners said last week they were hoping to win approval in the United States and Europe this year after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.

(Reporting by Ludwig Burger; editing by Thomas Seythal)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.